EMMA News and Press, Emmaus Life Sciences Incorporation From 05/04/21

Emmaus Life Sciences Reports Annual Financial Results for 2020 and Provides Updated Business Review -- Net Revenues Increased Despite COVID-19 Pandemic-Related Challenges -- -- Improved Overall Operating Results and Net Income vs. Net Loss in 2019 -- PR Newswire ...

Emmaus Life Sciences Provides Form 10-K Filing Update -- Audit Committee to Meet Next Week -- PR Newswire TORRANCE, Calif. , April 15, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA) , a commercial-stage biopharmaceutical company and lead...

Emmaus Life Sciences ([[EMMA]]) announces that it has entered into an agreement with Kainos Medicine to lead the preclinical development of its patented IRAK4 inhibitor (KM10544) as an anti-cancer drug.Kainos will receive $500K in cash and $500K in Emmaus shares for entering into the agr...

Emmaus Life Sciences Announces Collaboration with Kainos Medicine for Preclinical Development of IRAK4 Inhibitor as Potential Anti-Cancer Drug PR Newswire TORRANCE, Calif. , March 2, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA) , a commerc...

Emmaus Life Sciences Reports Increase in Sales Volume in 2020 PR Newswire TORRANCE, Calif. , Jan. 27, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA) , a leader in the treatment of sickle cell disease, reports that it sold 25,947 boxes of End...

Emmaus Life Sciences (EMMA): FY GAAP EPS of -$1.30.Revenue of $22.8M (+38.2% Y/Y).The company intends to file its 2020 Annual Report on Form 10-K with the SEC in or about March 2021.Press Release. For further details see: Emmaus Life Sciences reports FY 2019 results

Emmaus Life Sciences Reports Annual Financial Results for 2019 and Provides Business Review -- 2019 Net Revenues Increased 38% over 2018 -- -- Restated Annual Financial Results for 2018 Also Reported -- PR Newswire TORRANCE, Calif. , Jan. 25, 2021 /PR...

Michigan Revises Prior Authorization Criteria for Endari® TORRANCE, Calif. , Dec. 10, 2020 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, announced today that it was notified by the Michigan Departm...

Emmaus Life Sciences Launches Endari® Support Program TORRANCE, Calif. , Dec. 8, 2020 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA) , a leader in the treatment of sickle cell disease, announced today the launch of the Endari® Support Progr...

Emmaus Life Sciences ([[EMMA]]) announces that the Swiss Agency for Therapeutic Products has granted orphan drug status to Endari. Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.The drug also enjoys Orph...